Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Current Deferred Revenue (2016 - 2018)

Historic Current Deferred Revenue for ImmunityBio (IBRX) over the last 5 years, with Q4 2018 value amounting to $598000.0.

  • ImmunityBio's Current Deferred Revenue rose 1500.0% to $598000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $598000.0, marking a year-over-year increase of 1500.0%. This contributed to the annual value of $598000.0 for FY2018, which is 1500.0% up from last year.
  • As of Q4 2018, ImmunityBio's Current Deferred Revenue stood at $598000.0, which was up 1500.0% from $577000.0 recorded in Q3 2018.
  • ImmunityBio's Current Deferred Revenue's 5-year high stood at $598000.0 during Q4 2018, with a 5-year trough of $5000.0 in Q4 2015.
  • Moreover, its 5-year median value for Current Deferred Revenue was $501000.0 (2017), whereas its average is $407538.5.
  • In the last 5 years, ImmunityBio's Current Deferred Revenue plummeted by 9904.03% in 2015 and then soared by 384000.0% in 2016.
  • Over the past 5 years, ImmunityBio's Current Deferred Revenue (Quarter) stood at $521000.0 in 2014, then plummeted by 99.04% to $5000.0 in 2015, then skyrocketed by 3840.0% to $197000.0 in 2016, then soared by 163.96% to $520000.0 in 2017, then rose by 15.0% to $598000.0 in 2018.
  • Its Current Deferred Revenue stands at $598000.0 for Q4 2018, versus $577000.0 for Q3 2018 and $558000.0 for Q2 2018.